Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Dr. Patrick Brown is the Director of the Pediatric Leukemia Program at Kimmel Cancer Center at Johns Hopkins. He received his medical degree from Medical University of South Carolina College of Medicine and then completed his residency and fellowship at Johns Hopkins University School of Medicine. His research is focused on developing new therapies for childhood leukemia, and his lab has found that a gene called FLT3 (which was initially discovered by Dr. Brown's mentor, Dr. Don Small) that is particularly important in the types of childhood leukemia with low cure rates. His lab has also identified promising combinations of standard chemotherapy drugs and FLT3 inhibitors that can work together to more effectively kill leukemia cells.
Dr. Brown is now leading the first acute myeloid leukemia (AML) clinical trials of a FLT3 inhibitor combined with chemotherapy in children with leukemia through the Children's Oncology Group international network. In conjunction with these clinical trials, Dr. Brown's lab is performing further experiments in the laboratory to help optimize dosing, to develop a test to predict patient benefits from the new drugs, and to determine how leukemia cells are able to survive treatment.